Stockscreener 앱 받기
20.69
0.46%
-0.0986
전일 마감가:
$20.79
열려 있는:
$20.7
하루 거래량:
120.41K
Relative Volume:
0.05
시가총액:
$1.80B
수익:
$139.71M
순이익/손실:
$-209.36M
주가수익비율:
-6.9903
EPS:
-2.96
순현금흐름:
$-160.60M
1주 성능:
+0.85%
1개월 성능:
-4.63%
6개월 성능:
+102.49%
1년 성능:
+43.61%
1일 변동 폭
$20.45
$21.00
1주일 범위
$19.71
$21.02
52주 변동 폭
$8.58
$22.73
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
명칭
Syndax Pharmaceuticals Inc
전화
781-419-1400
주소
730 THIRD AVENUE, NEW YORK, MA
SNDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
20.70 | 1.81B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.75 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.21 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
363.08 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.21 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-16 | 재개 | H.C. Wainwright | Buy |
| 2025-09-10 | 재개 | Stifel | Buy |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-08-05 | 재확인 | BTIG Research | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-06-28 | 개시 | Jefferies | Buy |
| 2024-01-31 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-10-25 | 개시 | BofA Securities | Buy |
| 2023-10-11 | 개시 | Goldman | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-11 | 개시 | Guggenheim | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2023-01-03 | 개시 | JP Morgan | Overweight |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2022-04-11 | 개시 | H.C. Wainwright | Buy |
| 2022-02-15 | 개시 | Goldman | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-25 | 개시 | Citigroup | Buy |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-05-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-04 | 개시 | Robert W. Baird | Outperform |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 개시 | FBR & Co. | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-10-07 | 개시 | Guggenheim | Buy |
| 2016-03-28 | 개시 | Citigroup | Buy |
| 2016-03-28 | 개시 | JMP Securities | Mkt Outperform |
| 2016-03-28 | 개시 | Morgan Stanley | Overweight |
모두보기
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Several Syndax Pharmaceuticals Insiders Sell Shares Sending Potential Negative Signal - 富途资讯
Aug Momentum: Is Syndax Pharmaceuticals Inc a defensive stockTreasury Yields & Weekly Return Optimization Plans - baoquankhu1.vn
Syndax Pharmaceuticals (NASDAQ:SNDX) Share Price Crosses Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Syndax Pharmaceuticals, Inc. (SNDX): A Bull Case Theory - Finviz
Expanded Global Access To Revuforj Could Be A Game Changer For Syndax Pharmaceuticals (SNDX) - Sahm
First Week of March 20th Options Trading For Syndax Pharmaceuticals (SNDX) - Nasdaq
Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Last Year’s 62.5% Share Price Gain? - Yahoo Finance
Trading Systems Reacting to (SNDX) Volatility - Stock Traders Daily
Rate Hike: Will Syndax Pharmaceuticals Inc benefit from green energy policiesWeekly Profit Report & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Insider Buy: Will Syndax Pharmaceuticals Inc stock recover faster than peersJuly 2025 PreEarnings & AI Driven Stock Reports - Bộ Nội Vụ
Assessing Syndax Pharmaceuticals (SNDX) Valuation After Expanded Revuforj Access And Recent Leukemia Progress - Sahm
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Market Trends: Can Syndax Pharmaceuticals Inc disrupt its industryPortfolio Return Summary & Risk Controlled Stock Alerts - baoquankhu1.vn
New cancer drugs see rising demand as drugmaker shares 2025 sales - Stock Titan
Bearish Setup: Can Syndax Pharmaceuticals Inc disrupt its industryGDP Growth & Real-Time Sentiment Analysis - baoquankhu1.vn
Wall Street Zen Downgrades Syndax Pharmaceuticals (NASDAQ:SNDX) to Sell - MarketBeat
Market Trends: Will Syndax Pharmaceuticals Inc. (1T3) stock benefit from Fed rate cutsTrade Risk Report & Expert Verified Movement Alerts - ulpravda.ru
Why Syndax Pharmaceuticals Inc. stock could outperform in 2025Recession Risk & Real-Time Buy Zone Alerts - Улправда
Will Syndax Pharmaceuticals Inc. (1T3) stock benefit from Fed rate cutsJuly 2025 Gainers & Real-Time Chart Pattern Alerts - Улправда
How strong is Syndax Pharmaceuticals Inc. stock revenue growthDollar Strength & High Win Rate Trade Alerts - Улправда
Will Syndax Pharmaceuticals Inc. stock outperform Nasdaq indexQuarterly Investment Review & Real-Time Stock Entry Alerts - ulpravda.ru
Tech Rally: Can Syndax Pharmaceuticals Inc. stock beat analyst upgradesPortfolio Risk Summary & Low Risk High Win Rate Picks - Улправда
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading 9.8% HigherShould You Buy? - MarketBeat
Syndax (SNDX) Expands Global Access to Revuforj with New Partner - GuruFocus
Syndax, World Orphan Drug Alliance Collaborate to Expand Access to Revuforj for Leukemia - marketscreener.com
Syndax Pharmaceuticals and World Orphan Drug Alliance Announce Collaboration to Expand Access to Revuforj® in Emerging Markets - Quiver Quantitative
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S. - Chartmill
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 6.5%What's Next? - MarketBeat
Syndax Pharmaceuticals CEO to Present at 44th Annual J.P. Morgan Healthcare Conference | SNDX Stock News - Quiver Quantitative
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Published on: 2026-01-06 01:29:59 - moha.gov.vn
How Syndax Pharmaceuticals Inc. (SNDX) Affects Rotational Strategy Timing - Stock Traders Daily
Syndax Pharmaceuticals (NASDAQ:SNDX) Upgraded at Wall Street Zen - MarketBeat
Syndax Pharmaceuticals Q3 2025 Earnings Preview - MSN
Commit To Buy Syndax Pharmaceuticals At $13, Earn 21.5% Using Options - Nasdaq
Is Syndax Pharmaceuticals (NASDAQ:SNDX) Using Debt Sensibly? - 富途牛牛
Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 1-Year HighTime to Buy? - MarketBeat
(SNDX) Risk Channels and Responsive Allocation - Stock Traders Daily
SNDX (Syndax Pharmaceuticals) EV-to-OCF : -4.35 (As of Dec. 21, 2025) - GuruFocus
Syndax Pharmaceuticals (STU:1T3) EV-to-OCF : -4.13 (As of Dec. 21, 2025) - GuruFocus
Syndax Pharmaceuticals modernizes bylaws for electronic share issuance - MSN
How Syndax Pharmaceuticals Inc. stock reacts to inflationary pressures2025 Volatility Report & AI Enhanced Trading Alerts - Bölüm Sonu Canavarı
Syndax Pharmaceuticals Modernizes Bylaws for Electronic Share Issuance - TipRanks
Published on: 2025-12-19 14:41:17 - DonanımHaber
Assenagon Asset Management S.A. Sells 255,848 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Will Syndax Pharmaceuticals Inc. stock beat EPS estimates2025 Market Overview & Community Trade Idea Sharing - ulpravda.ru
Syndax Pharmaceuticals (STU:1T3) EV-to-OCF : -3.99 (As of Dec. 19, 2025) - GuruFocus
How currency fluctuations impact Syndax Pharmaceuticals Inc. stock2025 Market Sentiment & Safe Capital Allocation Plans - ulpravda.ru
Syndax Pharma: Continuing Execution In AML (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 52-Week HighWhat's Next? - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.42%
1.57%
자본화:
|
볼륨(24시간):